Summary: Evaluated ezetimibe with simvastatin versus placebo in patients with chronic kidney disease. The primary endpoint of first major atherosclerotic event (nonfatal MI, coronary death, stroke or arterial revascularization procedure) was reduced with ezetimibe and simvastatin. Note that there was not a ezetimibe alone arm, thus which drug caused to major effect is not able to be determined.
The Lancet, Volume 377, Issue 9784, Pages 2181 - 2192, 25 June 2011
Eponym: Study of Heart And Renal Protection